The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure

DOI: 10.1016/j.jacc.2004.09.041
Journal of the American College of Cardiology, 2004, 44, 2339-48.

#	Paper	IF	Citations
194	Current World Literature. **2005**, 14, 502-517		
193	Bibliography Current World Literature. **2005**, 20, 324-368		
192	Pathophysiology and treatment of alveolar□apillary dysfunction in chronic heart failure. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 641-648		
191	Effect of sildenafil on cardiac performance in patients with heart failure. **2005**, 96, 1436-40		95
190	Highlights of the year in JACC 2004. *Journal of the American College of Cardiology*, **2005**, 45, 137-53	15.1	1
189	Controversies in ventricular remodelling. **2006**, 367, 356-67		645
188	Bibliography. Current world literature. Clinical nephrology. **2006**, 15, 187-225		
187	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. **2006**, 5, 689-702		366
186	The emerging role for type 5 phosphodiesterase inhibition in heart failure. *Current Heart Failure Reports*, **2006**, 3, 123-8	2.8	12
185	Gas diffusion and alveolar-capillary unit in chronic heart failure. **2006**, 27, 2538-43		181
184	Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. **2007**, 115, 59-66		285
183	Potential role of phosphodiesterases in the development of multiple organ dysfunction. **2007**, 3, 18-30		
182	Effects of sildenafil on exercise capacity in hypoxic normal subjects. **2007**, 8, 155-63		59
181	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. **2008**, 294, H1398-406		129
180	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. **2007**, 19, 139-48		45
179	Exercise ventilation inefficiency in heart failure: pathophysiological and clinical significance. **2007**, 28, 673-8		58
178	Phosphodiesterase type 5: expanding roles in cardiovascular regulation. *Circulation Research*, **2007**, 101, 1084-95	15.7	164

177	Expert opinion on available options treating pulmonary arterial hypertension. **2007**, 8, 2247-65		30
176	PDE5 inhibitors beyond erectile dysfunction. **2007**, 19, 533-43		57
175	Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. **2007**, 116, 1555-62		394
174	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. **2007**, 15, 76-86		52
173	Phosphodiesterases. **2007**, 919-957		4
172	Pulmonary hypertension associated with left-sided heart disease. **2007**, 28, 233-41, x		158
171	Type 5 phosphodiesterase inhibition in heart failure: the next step. *Journal of the American College of Cardiology*, **2007**, 50, 2145-7	15.1	14
170	Long-term use of sildenafil in the therapeutic management of heart failure. *Journal of the American College of Cardiology*, **2007**, 50, 2136-44	15.1	256
169	Sildenafil may facilitate weaning in mechanically ventilated COPD patients: a report of three cases. **2007**, 35, 610-3		3
168	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. **2007**, 150, 567-76		42
167	Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients. **2007**, 37, 454-62		8
166	Why does chronic heart failure cause breathlessness and fatigue?. *Progress in Cardiovascular Diseases*, **2007**, 49, 366-84	8.5	91
165	[Novel indications for phosphodiesterase type 5 inhibitors]. **2007**, 102, 617-30		4
164	Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. *Cardiovascular Drugs and Therapy*, **2007**, 21, 171-94	3.9	61
163	Approach to patients with heart failure and pulmonary hypertension. *Current Treatment Options in Cardiovascular Medicine*, **2007**, 9, 302-9	2.1	7
162	Sildenafil analogs used for adulterating marihuana. **2008**, 182, e23-4		8
161	Sildenafil and phosphodiesterase-5 inhibitors for heart failure. *Current Heart Failure Reports*, **2008**, 5, 110-4	2.8	17
160	Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. **2008**, 83, 336-41		36

159	Control of pulmonary vascular tone during exercise in health and pulmonary hypertension. **2008**, 119, 242-63		37
158	Sildenafil improves the alveolar-capillary function in heart failure patients. *International Journal of Cardiology*, **2008**, 126, 68-72	3.2	13
157	TOxygen uptake efficiency slopeTin trained and untrained subjects exposed to hypoxia. *Respiratory Physiology and Neurobiology*, **2008**, 161, 167-73	2.8	4
156	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. *Circulation: Heart Failure*, **2008**, 1, 272-80	7.6	43
155	Effects of 5Tphosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. **2008**, 14, 189-97		92
154	Alveolar gas diffusion abnormalities in heart failure. **2008**, 14, 695-702		79
153	Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. **2008**, 29, 1681-7		177
152	Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates. **2008**, 294, H1357-64		13
151	Prognostic value and diagnostic potential of cardiopulmonary exercise testing in patients with chronic heart failure. *European Journal of Heart Failure*, **2008**, 10, 112-8	12.3	38
150	Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. *Circulation: Heart Failure*, **2008**, 1, 227-33	7.6	108
149	Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. **2008**, 118, 2190-9		83
148	Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. **2008**, 294, H1398-H1406		90
147	PDE5 inhibitors in non-urological conditions. **2009**, 15, 3521-39		24
146	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. *Nature Reviews Cardiology*, **2009**, 6, 349-55	14.8	25
145	Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. **2009**, 297, F362-70		90
144	Pulmonary venous hypertension or pulmonary hypertension due to left heart disease. **2009**, 27, 35-42		6
143	Treating heart failure with sildenafil. *Congestive Heart Failure*, **2009**, 15, 181-5		10
142	The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. **2009**, 106, 509-15		16

141	Phosphodiesterase inhibition in heart failure. *Heart Failure Reviews*, **2009**, 14, 255-63	5	51
140	Regulation of alveolar gas conductance by NO in man, as based on studies with NO donors and inhibitors of NO production. *Acta Physiologica*, **2009**, 196, 267-77	5.6	6
139	Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. **2009**, 50 Suppl 1, 34-43		35
138	Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. *Journal of Heart and Lung Transplantation*, **2009**, 28, 676-82	5.8	40
137	Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. *Journal of the American College of Cardiology*, **2009**, 54, 595-600	15.1	54
136	Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving □adrenoceptor linked mechanisms. **2009**, 61, 1146-52		3
135	Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study. **2009**, 182, 2850-5		21
134	Trying to succeed when the right ventricle fails. **2009**, 24, 239-45		23
133	Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. **2009**, 135, 1215-1222		51
132	The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review. **2009**, 7, 557-69		23
131	Relation of systemic venous return, pulmonary vascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving fontan palliation. **2010**, 105, 1169-75		64
130	Determinants of right ventricular failure in patients admitted with acute left heart failure. *Congestive Heart Failure*, **2010**, 16, 243-8		13
129	Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. **2010**, 64, 15-22		8
128	Clinician□s Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. **2010**, 122, 191-225		1120
127	Endothelium-dependent vasodilation is associated with exercise capacity in smokers and non-smokers. **2010**, 15, 119-25		17
126	[Pulmonary hypertension due to left heart disease: recommendations of the Cologne Consensus Conference 2010]. **2010**, 135 Suppl 3, S102-14		1
125	Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis. **2010**, 30, 259-65		7
124	The right heart and pulmonary circulation (III). The pulmonary circulation in heart failure. **2010**, 63, 334-45		8

123	Pulmonary hypertension with left-sided heart disease. *Nature Reviews Cardiology*, **2010**, 7, 648-59	14.8	101
122	La circulaci□n pulmonar en la insuficiencia cardiaca. **2010**, 63, 334-345		20
121	Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. **2011**, 45, 1551-8		11
120	Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S34-44	3.2	21
119	PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study. **2011**, 2011, 323-325		
118	Rodent models of pulmonary hypertension: harmonisation with the world health organisation□s categorisation of human PH. **2011**, 65, 15-34		63
117	Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome. **2011**, 6, 139-46		7
116	Sildenafil does not improve steady state cardiovascular hemodynamics, peak power, or 15-km time trial cycling performance at simulated moderate or high altitudes in men and women. **2011**, 111, 3031-40		18
115	Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. *Circulation: Heart Failure*, **2011**, 4, 198-206	7.6	44
114	PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. *Circulation: Heart Failure*, **2011**, 4, 8-17	7.6	298
113	Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?. **2011**, 124, 133-5		8
112	Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. **2011**, 300, H2272-9		58
111	PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. *Circulation: Heart Failure*, **2012**, 5, 653-9	7.6	98
110	Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. **2012**, 27, 262-72		13
109	Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. **2012**, 126, 942-51		29
108	Improvement in lung diffusion by endothelin A receptor blockade at high altitude. **2012**, 112, 20-5		28
107	Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. *European Journal of Heart Failure*, **2012**, 14, 82-90	12.3	87
106	Pulmonary circulation at exercise. **2012**, 2, 711-41		110

105	Pulmonary hypertension in left heart disease. **2012**, 21, 338-46		50
104	Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction. *Pulmonary Circulation*, **2012**, 2, 163-9	2.7	18
103	Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary hypertension). *Progress in Cardiovascular Diseases*, **2012**, 55, 104-18	8.5	14
102	Pulmonary hypertension due to left heart disease. **2012**, 126, 975-90		294
101	Peripheral circulation. **2012**, 2, 321-447		160
100	Sildenafil improves microvascular O2 delivery-to-utilization matching and accelerates exercise O2 uptake kinetics in chronic heart failure. **2012**, 303, H1474-80		42
99	Pulmonary hypertension in left heart disease: a review. *International Journal of Cardiology*, **2012**, 156, 253-8	3.2	7
98	Exercise oscillatory breathing and NT-proBNP levels in stable heart failure provide the strongest prediction of cardiac outcome when combining biomarkers with cardiopulmonary exercise testing. **2012**, 18, 313-20		11
97	Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute. *Canadian Journal of Cardiology*, **2012**, 28, 69-73	3.8	13
96	Complex Challenges of Pulmonary Hypertension. **2012**, 447-460		1
95	Endothelial dysfunction, arterial stiffness, and heart failure. *Journal of the American College of Cardiology*, **2012**, 60, 1455-69	15.1	292
94	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. *Current Heart Failure Reports*, **2012**, 9, 192-9	2.8	26
93	Right ventricular pulmonary hypertension. *Current Heart Failure Reports*, **2012**, 9, 303-8	2.8	4
92	Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: focus on phosphodiesterase inhibitors. *Future Cardiology*, **2012**, 8, 271-84	1.3	23
91	Treatment for pulmonary hypertension of left heart disease. *Current Treatment Options in Cardiovascular Medicine*, **2012**, 14, 319-27	2.1	12
90	Novel therapies in acute and chronic heart failure. *Pharmacology & Therapeutics*, **2012**, 135, 1-17	13.9	42
89	ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. *Trials*, **2013**, 14, 188	2.8	7
88	Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. *Current Heart Failure Reports*, **2013**, 10, 26-35	2.8	14

87	Relationships between maximal oxygen uptake and endothelial function in healthy male adults: a preliminary study. *Acta Diabetologica*, **2013**, 50, 135-41	3.9	25
86	Pulmonary hypertension due to left heart diseases. *Journal of the American College of Cardiology*, **2013**, 62, D100-8	15.1	437
85	Management of pulmonary hypertension in left heart disease. *Therapeutic Advances in Cardiovascular Disease*, **2013**, 7, 131-51	3.4	9
84	Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research. *Circulation: Heart Failure*, **2013**, 6, 584-93	7.6	22
83	The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study. *International Journal of Cardiology*, **2013**, 168, 60-5	3.2	25
82	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2013**, 309, 1268-77	27.4	762
81	Pulmonary hypertension associated with left heart disease. *Seminars in Respiratory and Critical Care Medicine*, **2013**, 34, 665-80	3.9	11
80	Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. *American Journal of Hypertension*, **2013**, 26, 342-50	2.3	12
79	Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. *European Journal of Heart Failure*, **2013**, 15, 119-22	12.3	35
78	Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?. *Congestive Heart Failure*, **2013**, 19, 99-103		18
77	Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects. *Circulation: Heart Failure*, **2013**, 6, 1268-83	7.6	19
76	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions. *Acta Cardiologica*, **2013**, 68, 495-504	0.9	5
75	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. *Haematologica*, **2013**, 98, 1359-67	6.6	35
74	Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. *Monaldi Archives for Chest Disease*, **2013**, 80, 177-83	2.7	12
73	Management of erectile dysfunction in hypertension: Tips and tricks. *World Journal of Cardiology*, **2014**, 6, 908-15	2.1	36
72	Tadalafil prevents acute heart failure with reduced ejection fraction in mice. *Cardiovascular Drugs and Therapy*, **2014**, 28, 493-500	3.9	18
71	Dyspnea in Eisenmenger syndrome and its amelioration by sildenafil: role of J receptors. *International Journal of Cardiology*, **2014**, 174, 574-8	3.2	6
70	Abnormalities in cardiopulmonary exercise testing ventilatory parameters in heart failure: pathophysiology and clinical usefulness. *Current Heart Failure Reports*, **2014**, 11, 80-7	2.8	20

69	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. *Acta Physiologica*, **2014**, 211, 314-33	5.6	12
68	The Right Heart. **2014**,		1
67	PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. *International Journal of Cardiology*, **2014**, 172, 581-7	3.2	30
66	Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. *Circulation: Heart Failure*, **2014**, 7, 367-77	7.6	75
65	Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure. *Journal of Cardiovascular Pharmacology*, **2015**, 66, 229-38	3.1	4
64	Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit. *Archives of Medical Science*, **2015**, 11, 190-8	2.9	12
63	Therapeutic potential of sildenafil in patients with chronic heart failure after cardiac surgery. *Journal of Indian College of Cardiology*, **2015**, 5, 1-8	0.2	
62	Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. *European Journal of Heart Failure*, **2015**, 17, 320-8	12.3	15
61	Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF. *Hypertension Research*, **2015**, 38, 829-39	4.7	11
60	PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. *American Heart Journal*, **2015**, 169, 813-822.e3	4.9	31
59	Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. *Canadian Journal of Cardiology*, **2015**, 31, 416-29	3.8	25
58	Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension. *Progress in Cardiovascular Diseases*, **2015**, 57, 473-9	8.5	7
57	The pathophysiology of pulmonary hypertension in left heart disease. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 309, L924-41	5.8	40
56	Pulmonary hypertension in heart failure with preserved ejection fraction. *Journal of Heart and Lung Transplantation*, **2015**, 34, 273-81	5.8	15
55	The Right Ventricle in Health and Disease. *Respiratory Medicine*, **2015**,	0.2	4
54	Pharmacologic and surgical interventions to improve functional capacity in heart failure. *Heart Failure Clinics*, **2015**, 11, 117-24	3.3	8
53	Increased consumption and vasodilatory effect of nitrite during exercise. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2016**, 310, L354-64	5.8	5
52	Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials. *Proteomics*, **2016**, 16, 894-905	4.8	9

51	Group 2 PH: Medical Therapy. *Progress in Cardiovascular Diseases*, **2016**, 59, 71-7	8.5	3
50	Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. *Circulation: Heart Failure*, **2016**, 9, e002729	7.6	53
49	Exercise Ventilation in COPD: Influence of Systolic Heart Failure. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2016**, 13, 693-699	2	22
48	Evaluation of Cardiac, Vascular, and Skeletal Muscle Function With MRI: Novel Physiological End Points in Cardiac Rehabilitation Research. *Canadian Journal of Cardiology*, **2016**, 32, S388-S396	3.8	5
47	Contribution of sport science to performance: Wheelchair rugby. **2016**, 172-198		
46	Sildenafil does not Improve Exercise Capacity under Acute Hypoxia Exposure. *International Journal of Sports Medicine*, **2016**, 37, 785-91	3.6	5
45	Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). *Pulmonary Circulation*, **2016**, 6, 161-7	2.7	6
44	Can sildenafil improve physical performance at altitude? Current scientific evidence. *Apunts Medicine De LÆsport*, **2016**, 51, 27-35	0.6	
43	Evolving Concepts of Pulmonary Hypertension Secondary to Left Heart Disease. *Current Heart Failure Reports*, **2016**, 13, 92-102	2.8	8
42	Increased Dead Space Ventilation Mediates Reduced Exercise Capacity in Systolic Heart Failure. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 1292-300	10.2	20
41	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. *Journal of Endocrinological Investigation*, **2016**, 39, 131-42	5.2	18
40	Phosphodiesterase Type 5 Inhibitors, Sport and Doping. *Current Sports Medicine Reports*, **2017**, 16, 443-447	1.9	11
39	Nitric oxide signalling in cardiovascular health and disease. *Nature Reviews Cardiology*, **2018**, 15, 292-316	14.8	259
38	Will we be singing a different tune on combined post- and pre-capillary pulmonary hypertension?. *European Respiratory Journal*, **2018**, 51,	13.6	2
37	Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support: Is There a Role for Pulmonary Vasodilators?. *Circulation: Heart Failure*, **2018**, 11, e004255	7.6	17
36	Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. *Hypertension*, **2018**, 71, 34-55	8.5	11
35	Pulmonary Hypertension Associated With Left-Sided Heart Disease. **2018**, 223-229		
34	The influence of pulmonary vascular pressures on lung diffusing capacity during incremental exercise in healthy aging. *Physiological Reports*, **2018**, 6, e13565	2.6	7

33	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. *BioMed Research International*, **2018**, 2018, 3293584	3	17
32	Pulmonary Hypertension and Heart Failure: A Dangerous Liaison. *Heart Failure Clinics*, **2018**, 14, 297-309	3.3	10
31	Sildenafil does not improve performance in 16.1 km cycle exercise time-trial in acute hypoxia. *PLoS ONE*, **2019**, 14, e0210841	3.7	5
30	Challenges in pulmonary hypertension associated with left heart disease. *Expert Review of Cardiovascular Therapy*, **2019**, 17, 461-472	2.5	1
29	Pulmonary Hypertension. **2019**, 327-341.e9		
28	Pulmonary hypertension in left heart disease. *Archives of Medical Science*, **2019**, 15, 262-273	2.9	14
27	Inhaled Iloprost and Oral Sildenafil Combination Therapy: Is it a Chance for Heart Transplant Candidacy?. *Heart Lung and Circulation*, **2020**, 29, 1039-1045	1.8	
26	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. *Endocrines*, **2020**, 1, 90-101	0.8	2
25	Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence. *Pharmacology & Therapeutics*, **2020**, 214, 107619	13.9	4
24	Proportional Assist Ventilation Improves Leg Muscle Reoxygenation After Exercise in Heart Failure With Reduced Ejection Fraction. *Frontiers in Physiology*, **2021**, 12, 685274	4.6	1
23	PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca Content. *Circulation Research*, **2021**, 129, 650-665	15.7	2
22	J receptor activity in idiopathic pulmonary hypertension and its expected change in the presence of pulmonary bed vasodilators. *Respiratory Physiology and Neurobiology*, **2021**, 294, 103742	2.8	
21	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. *Archivos De Cardiologia De Mexico*, **2015**, 85, 215-24	0.2	6
20	The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA). *Southern Medical Journal*, **2010**, 103, 116-20	0.6	4
19	The Right Ventricle: A Not-So-Innocent Bystander in Pulmonary Hypertension Due to Left Heart Disease. *Advances in Pulmonary Hypertension*, **2015**, 14, 79-87	0.5	3
18	Pathophysiology and treatment of alveolar-capillary dysfunction in chronic heart failure. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 641-648		
17	Treatment of severe pulmonary hypertension with sildenafil in a heart transplant candidate for advanced heart failure. *Cor Et Vasa*, **2009**, 51, 279-281	0.3	1
16	Left Ventricular Diastolic Heart Function and Pulmonary Hypertension. **2011**, 1183-1188		2

15	Pulmonale Hypertonie. **2011**, 309-334		
14	Pulmonary Hypertension in Congenital Heart Disease. **2014**, 2159-2199		
13	Left Heart Failure. **2014**, 209-221		
12	The Right Ventricle in Left Heart Failure. *Respiratory Medicine*, **2015**, 361-390	0.2	
11	Surgery, Devices, Transplantation and Other Interventional Options for the Treatment of Advanced Pulmonary Hypertension. **2016**, 283-306		
10	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. **2016**, 29-61		
9	Pulmonary Hypertension in Left Heart Disease. **2017**, 341-369		
8	OBSOLETE: Pulmonary Hypertension Associated with Left-Sided Heart Disease. **2018**,		
7	Stroke Volume Reserve Is an Independent Predictor of Survival and Need for Advanced Therapies in Systolic Heart Failure Patients.		
6	Effect of Sildenafil Citrate on Exercise Capacity in Athletes With Spinal Cord Injury. *International Journal of Sports Physiology and Performance*, **2020**, 1-5	3.5	1
5	Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial.. *Cardiology Research and Practice*, **2022**, 2022, 5681510	1.9	
4	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial. *European Journal of Heart Failure*,	12.3	1
3	Combined pre- and post-capillary pulmonary hypertension in left heart disease. *Heart Failure Reviews*,	5	2
2	Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.		1
1	Pulmonary hypertension associated with left-sided heart disease. **2017**, 147, w14395		0